Neuromodulators as a therapeutic strategy for epilepsy in post-COVID-19 patients

Puntos clave

• Neuromodulators may enhance epilepsy management in those recovering from COVID-19, indicating potential therapeutic benefits.
• Significant improvement was noted for 70% of patients with epilepsy who received neuromodulator treatment over 6 months.
• Assessment involved a comprehensive analysis of patient outcomes following neuromodulator intervention for epilepsy post-COVID-19.
• This highlights the need for further exploration of therapeutic options in post-viral neurological disorders.